{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:34:13Z","timestamp":1788633253850,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijantimicag.2024.107181","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T05:33:47Z","timestamp":1713677627000},"page":"107181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models"],"prefix":"10.1016","volume":"64","author":[{"given":"Niels","family":"Frimodt-M\u00f8ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon U.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-2404","authenticated-orcid":false,"given":"Michel","family":"Plattner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Huseby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Radmer Almind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Haldimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0798-0828","authenticated-orcid":false,"given":"Marina","family":"Gysin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Ercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7456-9182","authenticated-orcid":false,"given":"Diarmaid","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Vingsbo Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-0384","authenticated-orcid":false,"given":"Sven N.","family":"Hobbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0001","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107181_bib0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijantimicag.2015.03.008","article-title":"Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin\/clavulanic acid isolated in Spain","volume":"46","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107181_bib0003","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1093\/jac\/dkac225","article-title":"Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"27","key":"10.1016\/j.ijantimicag.2024.107181_bib0004","doi-asserted-by":"crossref","first-page":"10984","DOI":"10.1073\/pnas.1204073109","article-title":"Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin","volume":"109","author":"Matt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.diagmicrobio.2016.09.002","article-title":"Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae","volume":"86","author":"Smith","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107181_bib0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2017.03.006","article-title":"In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"88","author":"Kang","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0007","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dky546","article-title":"In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"74","author":"Juhas","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2024.107181_bib0008","doi-asserted-by":"crossref","first-page":"e01374","DOI":"10.1128\/AAC.01374-19","article-title":"Synergistic combinations and repurposed antibiotics active against the pandrug-resistant Klebsiella pneumoniae Nevada strain","volume":"63","author":"Brennan-Krohn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107181_bib0009","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41598-019-38634-3","article-title":"Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use","volume":"9","author":"Ishikawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2024.107181_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103652","article-title":"Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"73","author":"Becker","year":"2021","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.ijantimicag.2024.107181_bib0011","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1128\/AAC.03239-14","article-title":"In vivo efficacy of apramycin in murine infection models","volume":"58","author":"Meyer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0012","doi-asserted-by":"crossref","first-page":"e02585","DOI":"10.1128\/AAC.02585-17","article-title":"Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model","volume":"62","author":"Kang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0013","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ijantimicag.2024.107181_bib0014","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cmi.2020.12.004","article-title":"Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice","volume":"27","author":"Becker","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107181_bib0015","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cmi.2022.05.003","article-title":"Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia","volume":"28","author":"Aranzana-Climent","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107181_bib0016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12915-022-01304-4","article-title":"Optimization of the antimicrobial peptide Bac7 by deep mutational scanning","volume":"20","author":"Koch","year":"2022","journal-title":"BMC Biol"},{"issue":"Suppl D","key":"10.1016\/j.ijantimicag.2024.107181_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/31.suppl_D.55","article-title":"The mouse peritonitis model: present and future use","volume":"31","author":"Frimodt-M\u00f8ller","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107181_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106659","article-title":"Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia","volume":"60","author":"Gysin","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"17","key":"10.1016\/j.ijantimicag.2024.107181_bib0019","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.3390\/ijms21176133","article-title":"Epidemiologic, phenotypic, and structural characterization of aminoglycoside-resistance gene aac(3)-IV","volume":"21","author":"Plattner","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107181_bib0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021: a multicenter study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107181_bib0022","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1089\/mdr.2017.0101","article-title":"Evaluation of aminoglycoside and carbapenem resistance in a collection of drug-resistant Pseudomonas aeruginosa clinical Isolates","volume":"24","author":"Holbrook","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107181_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T18:56:31Z","timestamp":1727981791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0924857924000992"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107181","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107181"}}